Lummy Pharmaceutical: Wholly-owned subsidiary obtains marketing approval for finerenone API

Lummy Pharmaceutical announced that its wholly-owned subsidiary, Chongqing Lummy Longyu Pharmaceutical Co., Ltd., received the "Chemical API Marketing Application Approval Notice" for finerenone issued upon approval by the National Medical Products Administration. The API has been approved for domestic production and marketing, with the notice valid until September 9, 2031. Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist, and its formulation is used to treat adult patients with chronic kidney disease associated with type 2 diabetes. This approval will help enrich the company's product line and enhance its core competitiveness. There is uncertainty regarding the subsequent production and sales of the drug.